Product Code Database
Zeneca (officially Zeneca Group PLC) was a British multinational pharmaceutical company headquartered in London, United Kingdom. It was formed in June 1993 by the demerger of the pharmaceuticals and agrochemicals businesses of Imperial Chemical Industries into a separate company listed on the London Stock Exchange.
In 1999, Zeneca and the Sweden-based pharmaceutical company Astra AB merged to form AstraZeneca.
Zeneca's largest therapeutic area was oncology, in which its key products included Bicalutamide, Tamoxifen and Goserelin. Other key products included heart drug Atenolol.
In May 1998, Zeneca announced that Tom McKillop, then the head of its drugs division, would succeed Sir David Barnes as chief executive, with Barnes becoming non-executive chairman of the company. In November 1998, Zeneca announced that it would sell its Zeneca Specialties division, including its biocides, industrial colours, life science molecules, performance and intermediate chemicals and resins activities. On 11 December 1998, Zeneca and Astra AB announced a £48 billion merger. In February 1999, it was reported that Zeneca would sue the US Food and Drug Administration over its decision to allow Gensia Sicor to produce a generic version of its Anesthetic Propofol. The merger between Zeneca and Astra AB was completed in April 1999, forming AstraZeneca.
|
|
